Treating the Patient with High-risk MDS: Practical Strategies and Emerging Therapeutic Options

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: October 23, 2019
Expiration Date: October 23, 2020

Expected time to complete this activity as designed: 30 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

Almost one-third of patients are classified as higher risk with a median overall survival of less than 1.5 years. In this activity, Dr. David Sallman covers which factors will impact the selections of therapy. Additionally, he will review ongoing clinical trials of novel agents and combinations while outlining where these practice strategies and trials can be utilized.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, pharmacists and other allied healthcare professionals who provide care to patients with myelodysplastic syndromes.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Identify clinical-, patient-, and disease-related conditions that impact selection of therapy in high-risk MDS patients who have relapsed or are refractory to treatment with HMAs
  • Correlate these factors with recently approved agents or ongoing clinical trials of novel agents and combinations of agents being investigated for use in patients with high-risk MDS
  • Outline practical strategies developed in conjunction with clinical trials optimizing the use of novel agents in patients with high-risk relapsed/refractory MDS


Treating the Patient with High-risk MDS: Practical Strategies and Emerging Therapeutic Options – David A. Sallman, MD

Instructions for Participation and Credit

This activity is eligible for credit through October 23, 2020. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

David A. Sallman, MD
Assistant Member
Malignant Hematology Department
Moffitt Cancer Center
Tampa, Florida

Dr. David Sallman is an Assistant Member of the Malignant Hematology Department at Moffitt Cancer Center in Tampa, Florida. His research interests focus on the development of novel, targeted therapeutic strategies for patients with myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML) based on the underlying mutational drivers of the disease. Specifically, Dr. Sallman is involved in the study of the genetic drivers of myeloid diseases in order to improve prognostication for patients and also to allow for more personalized treatment. He has published significantly on this topic in peer-reviewed journals including Leukemia and Haematologica and this work is the foundation of clinical trials/translational studies designed to improve the quality of life and survival of patients with MDS. Dr. Sallman is also the principal investigator on multiple on-going studies focused on higher risk MDS.


Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.5 contact hours of Continuing Education Credit.
Universal Activity Number: 827-0000-19-026-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.


As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. David Sallman has received honoraria related to speakers’ bureau activities from AbbVie Inc., Agios, Celgene Corporation, Incyte Corporation, and Novartis AG. He has received grant support related to research activities from Celgene and Jazz Pharmaceuticals plc.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Andrea Mathis, Project Manager, Joan Meyer, RN, MHA, Executive Director, and Bill Stoff, Director of Operations, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Astex Pharmaceuticals, Celgene Corporation, and Takeda Oncology.

©2019 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.